Perez-Chada Lourdes M, Merola Joseph F, Armstrong April W, Gottlieb Alice B
From the Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts; Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California; Department of Dermatology, Icahn School of Medicine at Mt. Sinai, New York, New York, USA.
L.M. Perez-Chada, MD, MMSc, Department of Dermatology, Harvard Medical School, Brigham and Women's Hospital; J.F. Merola, MD, MMSc, Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women's Hospital; A.W. Armstrong, MD, MPH, Department of Dermatology, Keck School of Medicine, University of Southern California; A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mt. Sinai.
J Rheumatol Suppl. 2019 Jun;95:28-32. doi: 10.3899/jrheum.190124.
At the 2018 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the International Dermatology Outcome Measures (IDEOM) Psoriasis Working Group presented an overview of its efforts to enhance clinical care and research in both the clinical setting as well as in clinical trials for psoriasis. First, the group discussed the results of a Delphi survey conducted in collaboration with the American Academy of Dermatology to agree on a unique physician-reported global assessment to measure the quality of care delivered to patients with psoriasis and other chronic inflammatory dermatoses. Second, the group summarized its efforts to select outcome measures for "PsA symptoms" and "treatment satisfaction," 2 of the domains of the psoriasis core domain set that were established by IDEOM. Finally, the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) presented an update on its clinical, educational, and research missions to foster the development of combined clinics for psoriatic disease, increase disease awareness, and accelerate management.
在2018年银屑病和银屑病关节炎研究与评估小组(GRAPPA)年会上,国际皮肤病学疗效评估(IDEOM)银屑病工作组概述了其在临床环境以及银屑病临床试验中加强临床护理和研究的努力。首先,该小组讨论了与美国皮肤病学会合作进行的德尔菲调查结果,以商定一种独特的医生报告的整体评估方法,用于衡量为银屑病和其他慢性炎症性皮肤病患者提供的护理质量。其次,该小组总结了其为“银屑病关节炎症状”和“治疗满意度”选择疗效评估指标的努力,这是IDEOM确定的银屑病核心领域集的两个领域。最后,银屑病和银屑病关节炎诊所多中心推进网络(PPACMAN)介绍了其临床、教育和研究任务的最新情况,以促进银屑病疾病联合诊所的发展,提高疾病认知度,并加速管理。